• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1265741 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& q% F0 l9 {! ]3 R7 S
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
) v! [0 q3 [5 Z! u9 J+ Author Affiliations
2 d+ I7 Z& f- i- M5 T$ w7 \
( }# d9 \% r2 x5 `" d1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan , a0 W5 b6 v$ s1 d5 G
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
) t5 I, n. X( ^  w- P; j& h3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan # m7 R0 Z. f' J; S$ F8 L% U4 H
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan * }# J5 {( S) H+ C8 g! N
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 3 M' w3 X7 h- d. m* B( m
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
4 N# c, [/ ?) L: \; i* O1 w* P: u& k7Kinki University School of Medicine, Osaka 589-8511, Japan
# `8 Z8 @. l5 P9 Y1 L8Izumi Municipal Hospital, Osaka 594-0071, Japan
4 w7 ?) f. b7 _. l9 V' d6 e9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan * e$ D" u6 S0 S. ~' w! C
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
7 H! W1 a- F3 M+ fAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. & G( Z( o: n4 I: I9 ^

* o* j8 f$ n$ @5 t
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
' j7 ^- F$ m2 W9 e* l7 @( Y% [9 V1 b* M0 ?1 p- J& |  g7 W
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato ( T4 i1 v& ?* V. j

- V/ D3 B, F/ U* d6 U( w) C: yAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
6 \. c+ D, R% C# c4 a. g
9 N6 P( q7 ~! u9 w- q) g4 s* JPublished online on: Thursday, December 1, 2011 $ E5 ~% _" C! v

  N0 C/ t3 E2 K" A/ g' KDoi: 10.3892/ol.2011.507
5 ~. R* q" D1 W8 i6 O* ?$ ^) v. t+ U/ ^/ W0 j$ d
Pages: 405-410
, J6 T) \$ E6 C
: Y+ K. E8 {2 ?' L+ @9 vAbstract:
8 b% |" A% W& M4 W, C. ]S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.: D" a/ N" g$ q* I4 [
) H# L& Z, e# u, l6 E# D
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
. W# `3 z$ M8 eF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
- T3 q$ f& n4 a. Y3 z. e+ Author Affiliations% x8 g8 u' n( A( d, V
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
$ T  ?( Q7 e( y2Department of Thoracic Surgery, Kyoto University, Kyoto : R% e8 c8 {/ L; G. x
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
- I3 a3 i. b+ l/ s1 g&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 1 B# T5 q4 F$ b4 {, O; s
Received September 3, 2010.
! d" |0 W3 ]" e) b' E* BRevision received November 11, 2010.
) L' z7 p8 m1 t8 c/ Y: lAccepted November 17, 2010. : M- f( }  ?5 \+ y# G
Abstract  D/ x2 s" Q' h  i4 k
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. % j6 K  [0 Q. m" L, p! m
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
7 G, J+ T3 O* ?) T9 YResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
5 ?" [  u5 g# d2 K9 X( _% NConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 5 C; {1 w6 g- u
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。! r' M: d$ D( a9 D, U
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
5 C3 _* K6 Y+ c3 _- R
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy/ x  [1 X7 ]9 v8 _! h! V& F2 {% C
http://clinicaltrials.gov/ct2/show/NCT01523587
" v! V5 B7 l7 g3 F7 G6 t
! {  \1 X, x$ R6 g" C; S6 _BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC: ]) P0 [, W* {
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 7 o! b% o+ `4 y* g$ k
1 P; I1 m) l* Z$ f1 l) H
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
* E& y/ {3 Y) X6 z至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

) J# @( S( A% c  U没有副作用是第一追求,效果显著是第二追求。7 i5 [2 p( F, a. E: C4 }( n
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表